The combination of the I131 and NF-κB inhibition with either an IκB kinase (IKK) inhibitor Bay 11–7082 or p65 siRNA resulted in a greater decrease of thyroid cancer growth in vitro [20] and in a flank xenograft model in mice [21] than either therapy alone. Here, NFKB1 is linked to thyroid gland carcinoma.